The stem cell sector is fueled by innovation and rapid change. To keep you up-to-date, we recently released new coverage of the industry. Check it out and let us know what you think! [Read more…]
Current Bottlenecks in MSC Research: Widespread MSC Misconceptions
This is a guest post from RoosterBio, written by Jon Rowley. RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation.
We blogged several months ago about bottlenecks in the bioprocessing of Mesenchymal Stem Cells that are impeding their clinical translation. While the development of robust and scalable manufacturing methods, reduced cost of goods, and implementation of solid Quality Systems are all necessary for increased clinical use of MSCs, there are also current misconceptions surrounding MSCs, rooted in decades-old science, that are holding the field back. [Read more…]
Interview with Dr. Jon Rowley, CEO of RoosterBio – Radically Changing the Use of Stem Cells
![RoosterBio](https://bioinformant.wpengine.com/wp-content/uploads/2016/07/RoosterBio-Logo.jpg)
This article is an interview with the Founder and Chief Executive Officer (CEO) of RoosterBio, Dr. Jon Rowley. RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation.
Specifically, RoosterBio’s products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems.
In this interview, we explore how RoosterBio is “radically changing the use of stem cells.” Enjoy! [Read more…]
Why Perinatal Stem Cells Are Gaining Momentum
Recently back from the Perinatal Stem Cell Society Conference in Aspen, CO, I am excited to share new coverage of the stem cell market with you. At this event, experts from around the world shared cutting-edge research about perinatal tissues over the course of three days (March 2-4, 2016).
We also have interviews with stem cell executives released below, including an interview with Dr. Jon Rowley, Founder and CEO of RoosterBio, and Dr. Racheli Ofir, VP of Research & Intellectual Property at Pluristem Therapeutics. Enjoy this exclusive new content!
Did You See This Week’s Top Stem Cell News?
We’ve released new content on stem cell and cord blood markets that we are excited to share with you. Enjoy!
Pluristem is a clinical-stage biotechnology company that uses placental cells and a proprietary, 3D technology platform to develop cell therapies for a broad range of diseases. Pluristem Therapeutics specializes in placental-derived “PLX” cells, which are now being explored for applications that include critical limb ischemia (CLI), acute radiation syndrome (ARS), incomplete bone marrow engraftment, and more. [Read more…]